Skip to main content
Premium Trial:

Request an Annual Quote

What a Result! Wait, a Second...

Highly-cited biomarker studies tend to report larger effect estimates for associations than subsequent meta-analyses do, says a literature review published in the Journal of the American Medical Association. John Ioannidis and Orestis Panagiotou combed through the ISI Web of Science to find studies that had been cited more than 400 times and had been published in a highly cited journal, and they searched for meta-analyses of those studies. From this, they evaluated 35 highly cited associations. "For 30 of the 35 (86%), the highly cited studies had a stronger effect estimate than the largest study; for 3 the largest study was also the highly cited study; and only twice was the effect size estimate stronger in the largest than in the highly cited study," Ioannidis and Panagiotou write. Ioannidis tells [email protected] that "the key message is that results that seem spectacular are very interesting, but researchers need to wait for further validation from independent research teams and large-scale evidence."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.